| 1 | Role of Cathelicidins in Atherosclerosis and Associated Cardiovascular Diseases | 1.2 | 3 | Citations (PDF) |
| 2 | Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential | 2.8 | 15 | Citations (PDF) |
| 3 | Rheumatoid Arthritis: What Inflammation Do We Face? | 1.2 | 7 | Citations (PDF) |
| 4 | Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis | 3.5 | 8 | Citations (PDF) |
| 5 | The Role of Macrophages in the Pathogenesis of Atherosclerosis | 4.8 | 117 | Citations (PDF) |
| 6 | Creation of Mitochondrial Disease Models Using Mitochondrial DNA Editing | 3.5 | 15 | Citations (PDF) |
| 7 | The Role of Pericytes in Regulation of Innate and Adaptive Immunity | 3.5 | 23 | Citations (PDF) |
| 8 | Hypotheses on Atherogenesis Triggering: Does the Infectious Nature of Atherosclerosis Development Have a Substruction? | 4.8 | 15 | Citations (PDF) |
| 9 | HDL-Based Therapy: Vascular Protection at All Stages | 3.5 | 3 | Citations (PDF) |
| 10 | Impaired Mitochondrial Function in T-Lymphocytes as a Result of Exposure to HIV and ART | 4.8 | 6 | Citations (PDF) |
| 11 | The Role of Selenium in Atherosclerosis Development, Progression, Prevention and Treatment | 3.5 | 28 | Citations (PDF) |
| 12 | Oligosaccharides as Potential Therapeutics against Atherosclerosis | 4.3 | 5 | Citations (PDF) |
| 13 | Atheroprotective Aspects of Heat Shock Proteins | 4.5 | 14 | Citations (PDF) |
| 14 | Potential Application of the Plant-Derived Essential Oils for Atherosclerosis Treatment: Molecular Mechanisms and Therapeutic Potential | 4.3 | 5 | Citations (PDF) |
| 15 | Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets | 3.5 | 11 | Citations (PDF) |
| 16 | Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential | 3.5 | 17 | Citations (PDF) |
| 17 | Is There a Relationship between Adverse Pregnancy Outcomes and Future Development of Atherosclerosis? | 3.5 | 3 | Citations (PDF) |
| 18 | Regulatory T Cells in Atherosclerosis: Is Adoptive Cell Therapy Possible? | 2.8 | 4 | Citations (PDF) |
| 19 | Potential Use of Antioxidant Compounds for the Treatment of Inflammatory Bowel Disease | 4.4 | 16 | Citations (PDF) |
| 20 | Sialic acid as the potential link between lipid metabolism and inflammation in the pathogenesis of atherosclerosis | 1.4 | 15 | Citations (PDF) |
| 21 | BaZiBuShen alleviates cognitive deficits and regulates Sirt6/NRF2/HO-1 and Sirt6/P53-PGC-1α-TERT signaling pathways in aging mice | 5.6 | 39 | Citations (PDF) |
| 22 | Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing | 4.5 | 31 | Citations (PDF) |
| 23 | The Role of Mitochondrial DNA Mutations in Cardiovascular Diseases | 4.5 | 45 | Citations (PDF) |
| 24 | The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy | 3.5 | 68 | Citations (PDF) |
| 25 | Modulating mTOR Signaling as a Promising Therapeutic Strategy for Atherosclerosis | 4.5 | 26 | Citations (PDF) |
| 26 | Role of the mtDNA Mutations and Mitophagy in Inflammaging | 4.5 | 34 | Citations (PDF) |
| 27 | Local Accumulation of Lymphocytes in the Intima of Human Aorta Is Associated with Giant Multinucleated Endothelial Cells: Possible Explanation for Mosaicism of Atherosclerosis | 4.5 | 6 | Citations (PDF) |
| 28 | The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets | 4.5 | 84 | Citations (PDF) |
| 29 | Cholesterol Transport Dysfunction and Its Involvement in Atherogenesis | 4.5 | 31 | Citations (PDF) |
| 30 | Vaccination against Atherosclerosis: Is It Real? | 4.5 | 10 | Citations (PDF) |
| 31 | Atherosclerosis in HIV Patients: What Do We Know so Far? | 4.5 | 18 | Citations (PDF) |
| 32 | Functional Phenotypes of Intraplaque Macrophages and Their Distinct Roles in Atherosclerosis Development and Atheroinflammation | 3.5 | 25 | Citations (PDF) |
| 33 | Mitochondrial Implications in Cardiovascular Aging and Diseases: The Specific Role of Mitochondrial Dynamics and Shifts | 4.5 | 13 | Citations (PDF) |
| 34 | Somatic Mutations of Hematopoietic Cells Are an Additional Mechanism of Body Aging, Conducive to Comorbidity and Increasing Chronification of Inflammation | 3.5 | 5 | Citations (PDF) |
| 35 | The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment | 4.5 | 21 | Citations (PDF) |
| 36 | Novel Models of Crohn’s Disease Pathogenesis Associated with the Occurrence of Mitochondrial Dysfunction in Intestinal Cells | 4.5 | 2 | Citations (PDF) |
| 37 | Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors | 4.5 | 34 | Citations (PDF) |
| 38 | Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov | 3.5 | 15 | Citations (PDF) |
| 39 | Role of Impaired Mitochondrial Dynamics Processes in the Pathogenesis of Alzheimer’s Disease | 4.5 | 56 | Citations (PDF) |
| 40 | Interplay between Zn2+ Homeostasis and Mitochondrial Functions in Cardiovascular Diseases and Heart Ageing | 4.5 | 37 | Citations (PDF) |
| 41 | Aging of Vascular System Is a Complex Process: The Cornerstone Mechanisms | 4.5 | 9 | Citations (PDF) |
| 42 | Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis | 3.5 | 11 | Citations (PDF) |
| 43 | The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy | 4.5 | 28 | Citations (PDF) |
| 44 | Phenotype Diversity of Macrophages in Osteoarthritis: Implications for Development of Macrophage Modulating Therapies | 4.5 | 39 | Citations (PDF) |
| 45 | The Role of Mitochondrial Mutations in Chronification of Inflammation: Hypothesis and Overview of Own Data | 2.8 | 12 | Citations (PDF) |
| 46 | Atheroprotective Effects of Glycyrrhiza glabra L. | 4.3 | 20 | Citations (PDF) |
| 47 | Atherosclerosis Specific Features in Chronic Kidney Disease (CKD) | 3.5 | 28 | Citations (PDF) |
| 48 | From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease | 4.5 | 21 | Citations (PDF) |
| 49 | Effect of Glucose Levels on Cardiovascular Risk | 4.8 | 53 | Citations (PDF) |
| 50 | Significance of Mitochondrial Dysfunction in the Progression of Multiple Sclerosis | 4.5 | 28 | Citations (PDF) |
| 51 | Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis | 3.5 | 6 | Citations (PDF) |
| 52 | Molecular Mechanisms Underlying Pathological and Therapeutic Roles of Pericytes in Atherosclerosis | 4.5 | 21 | Citations (PDF) |
| 53 | Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease | 5.1 | 8 | Citations (PDF) |
| 54 | Involvement of Bacterial Extracellular Membrane Nanovesicles in Infectious Diseases and Their Application in Medicine | 5.1 | 4 | Citations (PDF) |
| 55 | Pathophysiological Aspects of the Development of Abdominal Aortic Aneurysm with a Special Focus on Mitochondrial Dysfunction and Genetic Associations | 2.6 | 12 | Citations (PDF) |
| 56 | Involvement of Oxidative Stress and the Innate Immune System in SARS-CoV-2 Infection | 2.8 | 45 | Citations (PDF) |
| 57 | Do Mitochondrial DNA Mutations Play a Key Role in the Chronification of Sterile Inflammation? Special Focus on Atherosclerosis | 2.4 | 6 | Citations (PDF) |
| 58 | Role of Telomeres Shortening in Atherogenesis: An Overview | 4.8 | 23 | Citations (PDF) |
| 59 | Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low‐Density Lipoproteins and Increasing Their Uptake by Macrophages | 4.3 | 58 | Citations (PDF) |
| 60 | Two Subpopulations of Human Monocytes That Differ by Mitochondrial Membrane Potential | 3.5 | 3 | Citations (PDF) |
| 61 | Autophagy and Mitophagy as Essential Components of Atherosclerosis | 4.8 | 44 | Citations (PDF) |
| 62 | Mutations of mtDNA in some Vascular and Metabolic Diseases | 2.4 | 9 | Citations (PDF) |
| 63 | Disturbance of Mitochondrial Dynamics and Mitochondrial Therapies in Atherosclerosis | 2.8 | 25 | Citations (PDF) |
| 64 | Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome | 4.5 | 149 | Citations (PDF) |
| 65 | Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk | 4.5 | 39 | Citations (PDF) |
| 66 | Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome | 2.4 | 15 | Citations (PDF) |
| 67 | ACE2 Is an Adjacent Element of Atherosclerosis and COVID-19 Pathogenesis | 4.5 | 16 | Citations (PDF) |
| 68 | Atherosclerosis as Mitochondriopathy: Repositioning the Disease to Help Finding New Therapies | 2.6 | 21 | Citations (PDF) |
| 69 | The Role of Mitochondrial Dysfunction in Vascular Disease, Tumorigenesis, and Diabetes | 3.6 | 60 | Citations (PDF) |
| 70 | Prospects for the Use of Sialidase Inhibitors in Anti-atherosclerotic Therapy | 2.6 | 6 | Citations (PDF) |
| 71 | BaZiBuShen alleviates altered testicular morphology and spermatogenesis and modulates Sirt6/P53 and Sirt6/NF-κB pathways in aging mice induced by D-galactose and NaNO2 | 5.6 | 69 | Citations (PDF) |
| 72 | Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside | 3.5 | 40 | Citations (PDF) |
| 73 | Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD | 4.5 | 109 | Citations (PDF) |
| 74 | Anti-Inflammatory Therapy for Atherosclerosis: Focusing on Cytokines | 4.5 | 70 | Citations (PDF) |
| 75 | The Role of Mitochondrial Mutations and Chronic Inflammation in Diabetes | 4.5 | 47 | Citations (PDF) |
| 76 | Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases | 4.5 | 30 | Citations (PDF) |
| 77 | Recognition of Oxidized Lipids by Macrophages and Its Role in Atherosclerosis Development | 3.5 | 71 | Citations (PDF) |
| 78 | Immunity in Atherosclerosis: Focusing on T and B Cells | 4.5 | 35 | Citations (PDF) |
| 79 | The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets | 4.5 | 41 | Citations (PDF) |
| 80 | Mitochondrial Dysfunction in Vascular Wall Cells and Its Role in Atherosclerosis | 4.5 | 69 | Citations (PDF) |
| 81 | Macrophages and Foam Cells: Brief Overview of Their Role, Linkage, and Targeting Potential in Atherosclerosis | 3.5 | 73 | Citations (PDF) |
| 82 | Fructus Ligustri Lucidi aqueous extract promotes calcium balance and short-chain fatty acids production in ovariectomized rats | 5.6 | 31 | Citations (PDF) |
| 83 | A comprehensive review on the phytochemistry, pharmacokinetics, and antidiabetic effect of Ginseng | 7.7 | 58 | Citations (PDF) |
| 84 | Some Molecular and Cellular Stress Mechanisms Associated with Neurodegenerative Diseases and Atherosclerosis | 4.5 | 20 | Citations (PDF) |
| 85 | Overview of OxLDL and Its Impact on Cardiovascular Health: Focus on Atherosclerosis | 4.0 | 294 | Citations (PDF) |
| 86 | Modification of Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Secretion by Monocytes Derived from Patients with Diabetic Foot Syndrome | 2.9 | 7 | Citations (PDF) |
| 87 | A Novel Insight at Atherogenesis: The Role of Microbiome | 3.7 | 23 | Citations (PDF) |
| 88 | NLPR3 Inflammasomes and Their Significance for Atherosclerosis | 3.5 | 33 | Citations (PDF) |
| 89 | NADPH Oxidases and Their Role in Atherosclerosis | 3.5 | 86 | Citations (PDF) |
| 90 | Endoplasmic Reticulum Stress in Macrophages: The Vicious Circle of Lipid Accumulation and Pro-Inflammatory Response | 3.5 | 42 | Citations (PDF) |
| 91 | Therapeutic Potential of Heme Oxygenase-1 in Aneurysmal Diseases | 5.9 | 10 | Citations (PDF) |
| 92 | Sialidase Activity in Human Blood Serum Has a Distinct Seasonal Pattern: A Pilot Study | 2.9 | 6 | Citations (PDF) |
| 93 | Genetics of Arterial-Wall-Specific Mechanisms in Atherosclerosis: Focus on Mitochondrial Mutations | 4.9 | 14 | Citations (PDF) |
| 94 | Lipid Metabolism in Macrophages: Focus on Atherosclerosis | 3.5 | 92 | Citations (PDF) |
| 95 | Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases | 4.5 | 26 | Citations (PDF) |
| 96 | Sex-Specific Features of Calcific Aortic Valve Disease | 4.5 | 69 | Citations (PDF) |
| 97 | Noninvasive Testing for Diagnosis of Stable Coronary Artery Disease in the Elderly | 4.5 | 9 | Citations (PDF) |
| 98 | Relationship Between Plasma Osteopontin and Arginine Pathway Metabolites in Patients With Overt Coronary Artery Disease | 2.9 | 8 | Citations (PDF) |
| 99 | Impact of Mitochondrial DNA Mutations on Carotid Intima-Media Thickness in the Novosibirsk Region | 2.8 | 8 | Citations (PDF) |
| 100 | Exposure to Zinc Oxide Nanoparticles Disrupts Endothelial Tight and Adherens Junctions and Induces Pulmonary Inflammatory Cell Infiltration | 4.5 | 23 | Citations (PDF) |
| 101 | Cellular Mechanisms of Human Atherogenesis: Focus on Chronification of Inflammation and Mitochondrial Mutations | 4.0 | 35 | Citations (PDF) |
| 102 | Mitochondrial Dysfunction and DNA Damage in the Context of Pathogenesis of Atherosclerosis | 3.5 | 68 | Citations (PDF) |
| 103 | The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation | 4.5 | 955 | Citations (PDF) |
| 104 | In Search for Genes Related to Atherosclerosis and Dyslipidemia Using Animal Models | 4.5 | 19 | Citations (PDF) |
| 105 | Carotid Atherosclerosis Progression in Postmenopausal Women Receiving a Mixed Phytoestrogen Regimen: Plausible Parallels with Kronos Early Estrogen Replacement Study | 2.9 | 3 | Citations (PDF) |
| 106 | Signaling Pathways and Key Genes Involved in Regulation of foam Cell Formation in Atherosclerosis | 4.8 | 86 | Citations (PDF) |
| 107 | The Role of Mitochondria in Cardiovascular Diseases | 2.9 | 88 | Citations (PDF) |
| 108 | The Link between Chronic Stress and Accelerated Aging | 3.5 | 119 | Citations (PDF) |
| 109 | Role of Phagocytosis in the Pro-Inflammatory Response in LDL-Induced Foam Cell Formation; a Transcriptome Analysis | 4.5 | 29 | Citations (PDF) |
| 110 | Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque | 4.5 | 95 | Citations (PDF) |
| 111 | Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy | 2.3 | 19 | Citations (PDF) |
| 112 | Signaling Pathways Potentially Responsible for Foam Cell Formation: Cholesterol Accumulation or Inflammatory Response—What is First? | 4.5 | 32 | Citations (PDF) |
| 113 | Clinical Effectiveness of a Combination of Black Elder Berries, Violet Herb, and Calendula Flowers in Chronic Obstructive Pulmonary Disease: The Results of a Double-Blinded Placebo-Controlled Study | 2.9 | 5 | Citations (PDF) |
| 114 | Oxidative Stress and Antioxidants in Atherosclerosis Development and Treatment | 2.9 | 116 | Citations (PDF) |
| 115 | Contribution of Neurotrophins to the Immune System Regulation and Possible Connection to Alcohol Addiction | 2.9 | 15 | Citations (PDF) |
| 116 | Possible Role of Mitochondrial DNA Mutations in Chronification of Inflammation: Focus on Atherosclerosis | 2.6 | 31 | Citations (PDF) |
| 117 | Mitochondrion as a Selective Target for the Treatment of Atherosclerosis: Role of Mitochondrial DNA Mutations and Defective Mitophagy in the Pathogenesis of Atherosclerosis and Chronic Inflammation | 4.1 | 65 | Citations (PDF) |
| 118 | Novel Approaches to Anti-atherosclerotic Therapy: Cell-based Models and Herbal Preparations (Review of Our Own Data) | 1.3 | 0 | Citations (PDF) |
| 119 | Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers? | 2.6 | 21 | Citations (PDF) |
| 120 | Changes in Mitochondrial Genome Associated with Predisposition to Atherosclerosis and Related Disease | 4.4 | 30 | Citations (PDF) |
| 121 | The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis | 4.5 | 133 | Citations (PDF) |
| 122 | MicroRNAs as Potential Biomarkers in Atherosclerosis | 4.5 | 113 | Citations (PDF) |
| 123 | Immune-Inflammatory Responses in Atherosclerosis: The Role of Myeloid Cells | 2.6 | 61 | Citations (PDF) |
| 124 | Heteroplasmic Variants of Mitochondrial DNA in Atherosclerotic Lesions of Human Aortic Intima | 4.4 | 22 | Citations (PDF) |
| 125 | Creation of Cybrid Cultures Containing mtDNA Mutations m.12315G>A and m.1555G>A, Associated with Atherosclerosis | 4.4 | 13 | Citations (PDF) |
| 126 | Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency | 3.2 | 19 | Citations (PDF) |
| 127 | Sialidase activity in human pathologies | 4.4 | 81 | Citations (PDF) |
| 128 | Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties | 2.4 | 25 | Citations (PDF) |
| 129 | Fructus Ligustri Lucidi preserves bone quality through the regulation of gut microbiota diversity, oxidative stress, TMAO and Sirt6 levels in aging miceAging, 2019, 11, 9348-9368 | 2.5 | 112 | Citations (PDF) |
| 130 | Profiling of risk of subclinical atherosclerosis: possible interplay of genetic and environmental factors as the update of conventional approach | 0.6 | 2 | Citations (PDF) |
| 131 | Creation of Cultures Containing Mutations Linked with Cardiovascular Diseases using Transfection and Genome Editing | 2.4 | 11 | Citations (PDF) |
| 132 | Trans-sialidase Associated with Atherosclerosis: Defining the Identity of a Key Enzyme Involved in the Pathology | 1.9 | 5 | Citations (PDF) |
| 133 | Human Disease Modelling Techniques: Current Progress | 2.2 | 4 | Citations (PDF) |
| 134 | Potential of anti-inflammatory agents for treatment of atherosclerosis | 2.9 | 144 | Citations (PDF) |
| 135 | New biomarkers for diagnosis and prognosis of localized prostate cancer | 14.1 | 54 | Citations (PDF) |
| 136 | The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2 | 1.1 | 276 | Citations (PDF) |
| 137 | The role of mitochondrial dysfunction in cardiovascular disease: a brief review | 4.1 | 431 | Citations (PDF) |
| 138 | Modified LDL Particles Activate Inflammatory Pathways in Monocyte-derived Macrophages: Transcriptome Analysis | 2.4 | 33 | Citations (PDF) |
| 139 | Mitochondrial diseases caused by mtDNA mutations: a mini-review | 2.1 | 74 | Citations (PDF) |
| 140 | Matrix metalloproteinases in pro-atherosclerotic arterial remodeling | 3.9 | 71 | Citations (PDF) |
| 141 | Modified lipoproteins as biomarkers of atherosclerosis | 6.0 | 23 | Citations (PDF) |
| 142 | Mitochondrial Genome Mutations Associated with Myocardial Infarction | 1.8 | 20 | Citations (PDF) |
| 143 | Cybrid Models of Pathological Cell Processes in Different Diseases | 4.6 | 22 | Citations (PDF) |
| 144 | LDL and foam cell formation as the basis of atherogenesis | 4.1 | 48 | Citations (PDF) |
| 145 | HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages | 2.9 | 16 | Citations (PDF) |
| 146 | Tumor Necrosis Factor-α and C-C Motif Chemokine Ligand 18 Associate with Atherosclerotic Lipid Accumulation In situ and In vitro | 2.4 | 22 | Citations (PDF) |
| 147 | Engineered Nanoparticles: Their Properties and Putative Applications for Therapeutic Approaches Utilizing Stem Cells for the Repair of Atherosclerotic Disease | 1.9 | 6 | Citations (PDF) |
| 148 | Chemokines and Relevant microRNAs in the Atherogenic Process | 2.6 | 11 | Citations (PDF) |
| 149 | The phenomenon of atherosclerosis reversal and regression: Lessons from animal models | 2.9 | 36 | Citations (PDF) |
| 150 | How do macrophages sense modified low-density lipoproteins? | 2.3 | 36 | Citations (PDF) |
| 151 | Impact of the cardiovascular system-associated adipose tissue on atherosclerotic pathology | 1.6 | 47 | Citations (PDF) |
| 152 | The effect of maximal vs submaximal exertion on postprandial lipid levels in individuals with and without coronary heart disease | 3.2 | 4 | Citations (PDF) |
| 153 | Mechanisms of foam cell formation in atherosclerosis | 3.8 | 621 | Citations (PDF) |
| 154 | Role of lipids and intraplaque hypoxia in the formation of neovascularization in atherosclerosis | 4.1 | 35 | Citations (PDF) |
| 155 | The impact of FOXO-1 to cardiac pathology in diabetes mellitus and diabetes-related metabolic abnormalities | 2.3 | 48 | Citations (PDF) |
| 156 | Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation | 2.3 | 61 | Citations (PDF) |
| 157 | Paraoxonase and atherosclerosis-related cardiovascular diseases | 2.9 | 129 | Citations (PDF) |
| 158 | Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c | 2.4 | 32 | Citations (PDF) |
| 159 | Thrombospondins: A Role in Cardiovascular Disease | 4.5 | 63 | Citations (PDF) |
| 160 | Role of Mitochondrial Genome Mutations in Pathogenesis of Carotid Atherosclerosis | 4.6 | 43 | Citations (PDF) |
| 161 | Small Dense Low‐Density Lipoprotein as Biomarker for Atherosclerotic Diseases | 4.6 | 354 | Citations (PDF) |
| 162 | Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives | 2.4 | 10 | Citations (PDF) |
| 163 | Use of Primary Macrophages for Searching Novel Immunocorrectors | 2.4 | 3 | Citations (PDF) |
| 164 | Potential use of buccal epithelium for genetic diagnosis of atherosclerosis using mtDNA mutations | 0.6 | 20 | Citations (PDF) |
| 165 | New markers of atherosclerosis: a threshold level of heteroplasmy in mtDNA mutations | 0.6 | 9 | Citations (PDF) |
| 166 | Is insulin pro-atherogenic at the cellular level? | 0.6 | 1 | Citations (PDF) |
| 167 | Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference? | 0.6 | 24 | Citations (PDF) |
| 168 | Monocyte Activation in Immunopathology: Cellular Test for Development of Diagnostics and Therapy | 2.9 | 37 | Citations (PDF) |
| 169 | Cellular Model of Atherogenesis Based on Pluripotent Vascular Wall Pericytes | 2.8 | 16 | Citations (PDF) |
| 170 | Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis | 2.5 | 313 | Citations (PDF) |
| 171 | The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Atherosclerosis | 4.5 | 81 | Citations (PDF) |
| 172 | Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women | 4.5 | 47 | Citations (PDF) |
| 173 | Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction) | 3.9 | 264 | Citations (PDF) |
| 174 | The role of miR-126 in embryonic angiogenesis, adult vascular homeostasis, and vascular repair and its alterations in atherosclerotic disease | 3.9 | 178 | Citations (PDF) |
| 175 | ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease | 3.3 | 91 | Citations (PDF) |
| 176 | Macrophage‐mediated cholesterol handling in atherosclerosis | 4.1 | 478 | Citations (PDF) |
| 177 | Immune-inflammatory responses in atherosclerosis: Role of an adaptive immunity mainly driven by T and B cells | 1.1 | 63 | Citations (PDF) |
| 178 | Links between atherosclerotic and periodontal disease | 2.9 | 104 | Citations (PDF) |
| 179 | Analysis of mitochondrial DNA heteroplasmic mutations A1555G, C3256T, T3336C, С5178А, G12315A, G13513A, G14459A, G14846А and G15059A in CHD patients with the history of myocardial infarction | 2.9 | 25 | Citations (PDF) |
| 180 | Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential | 7.7 | 41 | Citations (PDF) |
| 181 | Cellular mechanisms of human atherosclerosis: Role of cell-to-cell communications in subendothelial cell functions | 2.4 | 19 | Citations (PDF) |
| 182 | Anti-cytokine therapy for prevention of atherosclerosis | 7.7 | 28 | Citations (PDF) |
| 183 | Anti-atherosclerotic effects of garlic preparation in freeze injury model of atherosclerosis in cholesterol-fed rabbits | 7.7 | 28 | Citations (PDF) |
| 184 | CD68/macrosialin: not just a histochemical marker | 3.3 | 658 | Citations (PDF) |
| 185 | LDL electronegativity index: a potential novel index for predicting cardiovascular disease | 2.7 | 25 | Citations (PDF) |
| 186 | Role of gut microbiota in the modulation of atherosclerosis-associated immune response | 3.9 | 85 | Citations (PDF) |
| 187 | Endothelial Barrier and Its Abnormalities in Cardiovascular Disease | 2.9 | 218 | Citations (PDF) |
| 188 | T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview | 2.5 | 110 | Citations (PDF) |
| 189 | Human miR-221/222 in Physiological and Atherosclerotic Vascular Remodeling | 2.5 | 174 | Citations (PDF) |
| 190 | Development of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model Approach | 4.6 | 20 | Citations (PDF) |
| 191 | Mosaicism of Mitochondrial Genetic Variation in Atherosclerotic Lesions of the Human Aorta | 2.5 | 38 | Citations (PDF) |
| 192 | Heterogeneity of Tregs and the complexity in the IL-12 cytokine family signaling in driving T-cell immune responses in atherosclerotic vessels | 2.3 | 8 | Citations (PDF) |
| 193 | Myeloid dendritic cells: Development, functions, and role in atherosclerotic inflammation | 1.1 | 74 | Citations (PDF) |
| 194 | Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery | 2.2 | 56 | Citations (PDF) |
| 195 | Association of mutations in the mitochondrial genome with the subclinical carotid atherosclerosis in women | 2.9 | 16 | Citations (PDF) |
| 196 | Vascular stem/progenitor cells: current status of the problem | 2.7 | 33 | Citations (PDF) |
| 197 | Mutations of mitochondrial genome in carotid atherosclerosis | 2.4 | 14 | Citations (PDF) |
| 198 | Intestinal mucosal tolerance and impact of gut microbiota to mucosal tolerance | 3.9 | 72 | Citations (PDF) |
| 199 | Phenomenon of individual difference in human monocyte activation | 2.9 | 12 | Citations (PDF) |
| 200 | Study of the activated macrophage transcriptome | 2.9 | 28 | Citations (PDF) |
| 201 | Changes in transcriptome of macrophages in atherosclerosis | 4.1 | 92 | Citations (PDF) |
| 202 | Quantitative analysis of the expression of caspase 3 and caspase 9 in different types of atherosclerotic lesions in the human aorta | 2.9 | 16 | Citations (PDF) |
| 203 | Innervation of the arterial wall and its modification in atherosclerosis | 3.1 | 36 | Citations (PDF) |
| 204 | Association of mitochondrial mutations with the age of patients having atherosclerotic lesions | 2.9 | 12 | Citations (PDF) |
| 205 | Neutrophil's weapons in atherosclerosis | 2.9 | 54 | Citations (PDF) |
| 206 | Mutations of Mitochondrial DNA in Atherosclerosis and Atherosclerosis-Related Diseases | 2.4 | 29 | Citations (PDF) |
| 207 | Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation | 2.4 | 9 | Citations (PDF) |
| 208 | Phytoestrogen-Rich Dietary Supplements in Anti-Atherosclerotic Therapy in Postmenopausal Women | 2.4 | 20 | Citations (PDF) |
| 209 | Mitochondrial genome sequencing in atherosclerosis: what's next? | 2.4 | 10 | Citations (PDF) |
| 210 | Vascular Endothelium: Functioning in Norm, Changes in Atherosclerosis and Current Dietary Approaches to Improve Endothelial Function | 2.6 | 53 | Citations (PDF) |
| 211 | Intimal pericytes as the second line of immune defence in atherosclerosis | 2.4 | 24 | Citations (PDF) |
| 212 | Approach to Reduction of Blood Atherogenicity | 4.6 | 13 | Citations (PDF) |
| 213 | Role of Endoplasmic Reticulum Stress in Atherosclerosis and Diabetic Macrovascular Complications | 2.5 | 68 | Citations (PDF) |
| 214 | Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease | 4.5 | 84 | Citations (PDF) |
| 215 | Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects | 2.9 | 28 | Citations (PDF) |
| 216 | Low Density Lipoprotein-Containing Circulating Immune Complexes: Role in Atherosclerosis and Diagnostic Value | 2.5 | 45 | Citations (PDF) |
| 217 | Quantitative Assessment of Heteroplasmy of Mitochondrial Genome: Perspectives in Diagnostics and Methodological Pitfalls | 2.5 | 45 | Citations (PDF) |
| 218 | Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation | 2.9 | 70 | Citations (PDF) |
| 219 | Mitochondrial Aging and Age-Related Dysfunction of Mitochondria | 2.5 | 413 | Citations (PDF) |
| 220 | The complexity of cell composition of the intima of large arteries: focus on pericyte-like cells | 5.7 | 51 | Citations (PDF) |
| 221 | Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response | 2.5 | 58 | Citations (PDF) |
| 222 | Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters | 2.3 | 9 | Citations (PDF) |
| 223 | Changes of mitochondria in atherosclerosis: Possible determinant in the pathogenesis of the disease | 1.6 | 65 | Citations (PDF) |
| 224 | Lipid Regulators during Atherogenesis: Expression of LXR, PPAR, and SREBP mRNA in the Human Aorta | 2.4 | 14 | Citations (PDF) |
| 225 | Vascular Extracellular Matrix in Atherosclerosis | 1.3 | 107 | Citations (PDF) |
| 226 | Changes of lysosomes in the earliest stages of the development of atherosclerosis | 4.1 | 19 | Citations (PDF) |
| 227 | Intracellular Cholesterol Retention—New Target for Direct Anti-Atherosclerotic Therapy | 0.2 | 0 | Citations (PDF) |
| 228 | Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications | 2.4 | 30 | Citations (PDF) |
| 229 | Association of Mitochondrial Genetic Variation with Carotid Atherosclerosis | 2.4 | 45 | Citations (PDF) |
| 230 | Anti-Atherosclerotic Therapy Based on Botanicals | 1.7 | 49 | Citations (PDF) |
| 231 | Association of the level of heteroplasmy of the 15059G>A mutation in the MT-CYB mitochondrial gene with essential hypertension | 2.4 | 13 | Citations (PDF) |
| 232 | Direct anti-atherosclerotic therapy preventing intracellular cholesterol retention | 0.3 | 1 | Citations (PDF) |
| 233 | Mitochondrial Mutations are Associated with Atherosclerotic Lesions in the Human Aorta | 3.5 | 51 | Citations (PDF) |
| 234 | Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology | 7.7 | 39 | Citations (PDF) |
| 235 | Widespread distribution of HLA-DR-expressing cells in macroscopically undiseased intima of the human aorta: A possible role in surveillance and maintenance of vascular homeostasis | 1.1 | 21 | Citations (PDF) |
| 236 | Monocytes as a diagnostic marker of cardiovascular diseases | 1.1 | 132 | Citations (PDF) |
| 237 | Mitochondrial dysfunction and mitochondrial DNA mutations in atherosclerotic complications in diabetes | 2.4 | 24 | Citations (PDF) |
| 238 | Pluronic Block Copolymers Inhibit Low Density Lipoprotein Self‐Association | 1.4 | 8 | Citations (PDF) |
| 239 | Diagnostic and Prognostic Value of Low Density Lipoprotein-Containing Circulating Immune Complexes in Atherosclerosis | 4.4 | 24 | Citations (PDF) |
| 240 | Mutation C3256T of Mitochondrial Genome in White Blood Cells: Novel Genetic Marker of Atherosclerosis and Coronary Heart Disease | 2.4 | 30 | Citations (PDF) |
| 241 | Musashi-1 expression in atherosclerotic arteries and its relevance to the origin of arterial smooth muscle cells: Histopathological findings and speculations | 1.6 | 9 | Citations (PDF) |
| 242 | Correlation between lipid deposition, immune-inflammatory cell content and MHC class II expression in diffuse intimal thickening of the human aorta | 1.6 | 23 | Citations (PDF) |
| 243 | The Interaction of Plasma Sialylated and Desialylated Lipoproteins with Collagen from the Intima and Media of Uninvolved and Atherosclerotic Human Aorta | 1.6 | 8 | Citations (PDF) |
| 244 | The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease | 3.9 | 93 | Citations (PDF) |
| 245 | Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension | 3.3 | 65 | Citations (PDF) |
| 246 | Lipid-Lowering Effects of Time-Released Garlic Powder Tablets in Double-Blinded Placebo-Controlled Randomized Study | 2.7 | 74 | Citations (PDF) |
| 247 | Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study | 2.4 | 100 | Citations (PDF) |
| 248 | Title is missing! | 3.3 | 10 | Citations (PDF) |
| 249 | Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions | 1.6 | 70 | Citations (PDF) |
| 250 | Antioxidant content in low density lipoprotein and lipoprotein oxidation<i>in vivo</i>and<i>in vitro</i> | 2.8 | 27 | Citations (PDF) |
| 251 | Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro | 1.6 | 122 | Citations (PDF) |
| 252 | Effects of garlic on atherosclerosis | 2.9 | 77 | Citations (PDF) |
| 253 | Metabolism of Native and Naturally Occurring Multiple Modified Low Density Lipoprotein in Smooth Muscle Cells of Human Aortic Intima | 2.9 | 63 | Citations (PDF) |
| 254 | In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells | 1.4 | 45 | Citations (PDF) |
| 255 | Similarity Between Naturally Occurring Modified Desialylated, Electronegative and Aortic Low Density Lipoprotein | 2.8 | 27 | Citations (PDF) |
| 256 | Diagnostic value of immune cholesterol as a marker for atherosclerosis | 2.2 | 9 | Citations (PDF) |
| 257 | Naturally Occurring Modified Low Density Lipoproteins Are Similar if Not Identical: More Electronegative and Desialylated Lipoprotein Subfractions | 2.9 | 49 | Citations (PDF) |
| 258 | Direct Anti-atherosclerosis-related Effects of Garlic | 4.1 | 60 | Citations (PDF) |
| 259 | Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease | 1.2 | 55 | Citations (PDF) |
| 260 | Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine | 1.6 | 10 | Citations (PDF) |
| 261 | Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency | 1.6 | 115 | Citations (PDF) |
| 262 | Lipids in cells of atherosclerotic and uninvolved human aorta | 2.9 | 21 | Citations (PDF) |
| 263 | In vitro models of antiatherosclerotic effects of cardiovascular drugs | 1.9 | 122 | Citations (PDF) |
| 264 | Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture | 1.6 | 46 | Citations (PDF) |
| 265 | Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: Separation from native lipoprotein by affinity chromatography | 2.1 | 79 | Citations (PDF) |
| 266 | Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells | 2.9 | 68 | Citations (PDF) |
| 267 | Neutral glycolipids of atherosclerotic plaques and unaffected human aorta tissue | 0.2 | 10 | Citations (PDF) |
| 268 | Insolubilization of low density lipoprotein induces cholesterol accumulation in cultured subendothelial cells of human aorta | 1.6 | 29 | Citations (PDF) |
| 269 | Ganglioside content and composition of cells from normal and atherosclerotic human aorta | 1.6 | 25 | Citations (PDF) |
| 270 | Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins | 2.1 | 124 | Citations (PDF) |
| 271 | Association of low-density lipoprotein with particulate connective tissue matrix components enhances cholesterol accumulation in cultured subendothelial cells of human aorta | 3.6 | 33 | Citations (PDF) |
| 272 | The gangliosides of adult human aorta: intima, media and plaque | 0.2 | 35 | Citations (PDF) |
| 273 | Low‐Density Lipoprotein Apheresis and Regression of Atherosclerotic Plaque In Vitro | 1.8 | 4 | Citations (PDF) |
| 274 | Effect of cyclic AMP on lipid accumulation and metabolism in human atherosclerotic aortic cells | 1.6 | 14 | Citations (PDF) |
| 275 | Adult human aortic cells in primary culture: heterogeneity in shape | 1.3 | 24 | Citations (PDF) |
| 276 | Primary RIA screening of hybridoma supernatants without use of a negative control | 1.5 | 1 | Citations (PDF) |
| 277 | Mitochondrial mutations associated with cardiac angina | 0.6 | 4 | Citations (PDF) |
